<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03700437</url>
  </required_header>
  <id_info>
    <org_study_id>IUSCC-0662</org_study_id>
    <nct_id>NCT03700437</nct_id>
  </id_info>
  <brief_title>Fasting-mimicking Diet With Chemo-immunotherapy in Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Randomized Controlled Pilot Study to Evaluate Fasting-mimicking Diet in Patients Receiving Chemo-immunotherapy for Treatment of Metastatic Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn the effects of fasting on cancer cells while you get&#xD;
      maintenance treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cancer cells use an increased supply of glucose to make energy and do not have protection&#xD;
      against fasting that normal cells do. Because of this, researchers would like to study how&#xD;
      fasting may help chemotherapy target cancer cells instead of normal cells. Initial studies&#xD;
      suggest that fasting may decrease the side effects of chemotherapy and increase the chances&#xD;
      of your cancer responding to the chemotherapy. Patient populations will have non-small cell&#xD;
      lung cancer in which chemo-immunotherapy with carboplatin/pemetrexed and pembrolizumab have&#xD;
      been recommended to treat the cancer as part of standard care.&#xD;
&#xD;
      Primary Objective 1. To determine the feasibility and compliance of administering a&#xD;
      fasting-mimicking diet (FMD) in patients with advanced NSCLC receiving maintenance therapy&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
      1. To assess a patient's willingness to fast for second cycle&#xD;
&#xD;
      Correlative Objectives&#xD;
&#xD;
        1. To assess DNA damage via measurement of γ-Η2ΑΧ foci in PBMCs at baseline and following&#xD;
           one cycle of FMD (day 21 or day 28)&#xD;
&#xD;
        2. To assess spheroid formation from circulating tumor cells (CTCs) isolated from patients&#xD;
           post FMD as compared to baseline (prior to fasting)&#xD;
&#xD;
        3. To measure the changes in immune markers prior to and after administering the FMD&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2018</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of the patients who can finish the FMD without serious adverse events</measure>
    <time_frame>Between screening/baseline (28 to 4 days before Cycle 1 Day 1) and Cycle 1 Day 21 or 28 (Cylces last 21 or 28 days, based on treatment)</time_frame>
    <description>To assess feasibility, compliance will be measured by a daily log</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Fasting-Mimicking Diet (FMD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the intervention arm (FMD) will be provided with Chemolieve®, a plant-based FMD that provides ~300 calories/fasting day and includes all the food to be consumed during the dietary intervention including supplements&#xD;
Subjects will start the diet 3 days prior to chemo-immunotherapy and continue on the first day of chemo-immunotherapy for the first 4 cycles of therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fasting-Mimicking Diet</intervention_name>
    <description>Chemo-immunotherapy + FMD (fast-mimicking diet)</description>
    <arm_group_label>Fasting-Mimicking Diet (FMD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥ 18 years at the time of informed consent&#xD;
&#xD;
          2. Ability to provide written informed consent and HIPAA authorization&#xD;
&#xD;
          3. Eastern cooperative group (ECOG) performance status of 0 to 2&#xD;
&#xD;
          4. Histologically confirmed Non-Small Cell Lung Cancer (NSCLC) and have advanced disease.&#xD;
&#xD;
          5. BMI ≥ 19&#xD;
&#xD;
          6. Patients should be on maintenance therapy for advanced NSCLC as defined as treatment&#xD;
             with single agent immunotherapy, single agent chemotherapy plus immunotherapy or&#xD;
             single agent molecularly targeted therapy for a minimum of 2 months prior to study&#xD;
             entry&#xD;
&#xD;
          7. If a patient is on a treatment that lowers their ANC, their ANC has to be ≥ 1500 on&#xD;
             the first day of fasting&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Self-reported weight loss of &gt; 10% in the 6 weeks prior to study entry&#xD;
&#xD;
          2. History of diabetes mellitus or patients with a known recent elevated A1c &gt; 6&#xD;
&#xD;
          3. History of symptomatic hypoglycemia&#xD;
&#xD;
          4. Prior therapies with inhibitors of IGF-1 such as&#xD;
&#xD;
               1. Linsitinib&#xD;
&#xD;
               2. Picropodophyllin&#xD;
&#xD;
          5. Concurrent use of somatostatin&#xD;
&#xD;
          6. Concurrent use of immunosuppressive medications including sirolimus, tacrolimus,&#xD;
             mycophenolate mofetil, azathioprine, prednisone, dexamethasone, or cyclosporine&#xD;
&#xD;
          7. Significant food allergies (screening checklist in Appendix 3) which would make the&#xD;
             subject unable to consume the food provided&#xD;
&#xD;
          8. History or current evidence of any medical or psychiatric condition, therapy that may&#xD;
             confound the results of the trial, interfere with the subject's participation for the&#xD;
             full duration of the trial, or is not in the best interest of the participating&#xD;
             subject as deemed by the treating investigator.&#xD;
&#xD;
          9. Pregnant or lactating females are not eligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shadia Jalal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maggie Uhrich, RN</last_name>
    <phone>1 317-274-4505</phone>
    <email>muhrich@iu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eskenazi Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maggie Uhrich, RN</last_name>
      <phone>317-274-4505</phone>
      <email>muhrich@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Shadia Jalal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maggie Uhrich</last_name>
      <phone>317-274-4505</phone>
      <email>muhrich@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Shadia Jalal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin &amp; Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maggie Uhrich, RN</last_name>
      <phone>317-274-4505</phone>
      <email>muhrich@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Shadia Jalal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Shadia Jalal</investigator_full_name>
    <investigator_title>Associate Professor of Clinical Medicine</investigator_title>
  </responsible_party>
  <keyword>fasting</keyword>
  <keyword>diet</keyword>
  <keyword>chemo-immunotherapy</keyword>
  <keyword>lung cancer</keyword>
  <keyword>circulating tumor cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

